These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27325183)

  • 1. Targeting the complement cascade: novel treatments coming down the pike.
    Thurman JM; Le Quintrec M
    Kidney Int; 2016 Oct; 90(4):746-52. PubMed ID: 27325183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement and kidney disease.
    Cook HT
    Curr Opin Nephrol Hypertens; 2013 May; 22(3):295-301. PubMed ID: 23508058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.
    Anliker-Ort M; Dingemanse J; van den Anker J; Kaufmann P
    Front Immunol; 2020; 11():599417. PubMed ID: 33362783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic complement inhibition – from experimental to clinical medicine.
    Lappegård KT; Bjerre A; Tjønnfjord GE; Mollnes TE
    Tidsskr Nor Laegeforen; 2015 Oct; 135(19):1745-9. PubMed ID: 26486669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of complement inhibition in kidney transplantation.
    Legendre C; Sberro-Soussan R; Zuber J; Frémeaux-Bacchi V
    Br Med Bull; 2017 Dec; 124(1):5-17. PubMed ID: 29069327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of complement inhibitors in transplantation.
    Frémeaux-Bacchi V; Legendre CM
    Kidney Int; 2015 Nov; 88(5):967-73. PubMed ID: 26376132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement and the Kidney: An Overview.
    Thurman JM
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):86-94. PubMed ID: 32553250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement inhibitors are not useful in secondary hemolytic uremic syndromes.
    Duineveld C; Wetzels JFM
    Kidney Int; 2019 Oct; 96(4):829-833. PubMed ID: 31543154
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic regulation of complement in patients with renal disease - where is the promise?
    Thurman JM
    Clin Nephrol; 2012 May; 77(5):413-23. PubMed ID: 22551888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement in glomerular diseases.
    Tan Y; Zhao MH
    Nephrology (Carlton); 2018 Oct; 23 Suppl 4():11-15. PubMed ID: 30298653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecules Great and Small: The Complement System.
    Mathern DR; Heeger PS
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1636-50. PubMed ID: 25568220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
    Okumi M; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():9-13. PubMed ID: 26988663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The renaissance of complement therapeutics.
    Ricklin D; Mastellos DC; Reis ES; Lambris JD
    Nat Rev Nephrol; 2018 Jan; 14(1):26-47. PubMed ID: 29199277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver transplantation for aHUS: still needed in the eculizumab era?
    Coppo R; Bonaudo R; Peruzzi RL; Amore A; Brunati A; Romagnoli R; Salizzoni M; Galbusera M; Gotti E; Daina E; Noris M; Remuzzi G
    Pediatr Nephrol; 2016 May; 31(5):759-68. PubMed ID: 26604087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
    Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
    Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement-mediated kidney diseases.
    Poppelaars F; Thurman JM
    Mol Immunol; 2020 Dec; 128():175-187. PubMed ID: 33137606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
    Fakhouri F; Frémeaux-Bacchi V; Loirat C
    Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement inhibitors are useful in secondary hemolytic uremic syndromes.
    Caravaca-Fontan F; Praga M
    Kidney Int; 2019 Oct; 96(4):826-829. PubMed ID: 31543153
    [No Abstract]   [Full Text] [Related]  

  • 19. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.
    Zimmerhackl LB; Hofer J; Cortina G; Mark W; Würzner R; Jungraithmayr TC; Khursigara G; Kliche KO; Radauer W
    N Engl J Med; 2010 May; 362(18):1746-8. PubMed ID: 20445192
    [No Abstract]   [Full Text] [Related]  

  • 20. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.
    Le Clech A; Simon-Tillaux N; Provôt F; Delmas Y; Vieira-Martins P; Limou S; Halimi JM; Le Quintrec M; Lebourg L; Grangé S; Karras A; Ribes D; Jourde-Chiche N; Rondeau E; Frémeaux-Bacchi V; Fakhouri F
    Kidney Int; 2019 Jun; 95(6):1443-1452. PubMed ID: 30982675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.